Immunocore to present at upcoming investor conferences

Rhea-AI Summary

AeroVironment (NASDAQ: AVAV) has scheduled its third quarter fiscal year 2025 financial results announcement for Tuesday, March 4, 2025, after market close. The company will host a conference call and live audio webcast at 4:30 p.m. Eastern Time on the same day.

The earnings call will feature presentations from key executives including Wahid Nawabi (Chairman, President, and CEO), Kevin P. McDonnell (Senior VP and CFO), and Jonah Teeter-Balin (VP of Corporate Development and Investor Relations).

Investors can participate by registering through the provided link up to 10 minutes before the event. The webcast will be accessible through AeroVironment's Investor Relations website, with an audio replay available shortly after the event.

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April.

                  Kempen Life Sciences Conference
                  1x1 and small group meetings: Thursday, April 3, 2025

                  Needham Virtual Healthcare Conference
                  Fireside Chat: Wednesday, April 9, 2025, at 2:15 p.m. EDT

Where relevant, the presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Investor Relations

Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When will AeroVironment (AVAV) report Q3 2025 earnings?

AeroVironment will report Q3 FY2025 earnings on Tuesday, March 4, 2025, after market close, followed by a conference call at 4:30 p.m. ET.

How can investors join AVAV's Q3 2025 earnings call?

Investors can register for the call through the provided registration URL up to 10 minutes before the event starts at 4:30 p.m. ET.

Who will be presenting at AeroVironment's Q3 2025 earnings call?

The call will feature Wahid Nawabi (Chairman, President, CEO), Kevin P. McDonnell (CFO), and Jonah Teeter-Balin (VP of Corporate Development and IR).

Where can I access the replay of AVAV's Q3 2025 earnings call?

An audio replay will be available on AeroVironment's Investor Relations website at http://investor.avinc.com shortly after the event.